Future perspectives in the development of new anti-inflammatory protocols for CF include pre-clinical studies based on agents able to interfere with the TLR4/NFκB signaling pathway, including promising natural products (such as aged garlic extracts and their constituents S-allyl-Cysteine and S1-propenyl- cysteine) and miRNA-based therapeutic biomolecules targeting the TLR4/NFκB pathway. This evidence concerns the gene NFKB1 and cystic fibrosis.